FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person [*] <u>Rider Michael J</u>		2. Issuer Name and Ticker or Trading Symbol <u>RESMED INC</u> [RMD]		ionship of Reporting Person all applicable) Director Officer (give title	10% Owner Other (specify	
(Last) (First) (Middle) 9001 SPECTRUM CENTER BLVD		3. Date of Earliest Transaction (Month/Day/Year) 11/11/2024		below) Global General	below) Counsel	
(Street) SAN DIEGO CA	92123	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi X	Individual or Joint/Group Filing (Check Applicable Li X Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (li 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	 Transaction(s) (Instr. 3 and 4) 		(Instr. 4)
ResMed Common Stock	11/11/2024		F ⁽¹⁾		684.979	D	\$252.38	9,803	D	
ResMed Common Stock	11/11/2024		F ⁽²⁾		134.303	D	\$252.38	9,669	D	
ResMed Common Stock	11/11/2024		F ⁽³⁾		172.312	D	\$252.38	9,497	D	
ResMed Common Stock	11/11/2024		F ⁽⁴⁾		136.837	D	\$252.38	9,360	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	2. Conversion or Exercise Price of Derivative Security	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Derivative		Expiration Date				8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	

Explanation of Responses:

1. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023.

2. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/18/2021.

3. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022.

4. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/19/2020.

Michael J. Rider, Global General Counsel and Secretary

<u>11/12/2024</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.